trending Market Intelligence /marketintelligence/en/news-insights/trending/D1OvnyT_N3AZaHfZaFyl5Q2 content esgSubNav
In This List

Eidos Therapeutics appoints former Portola executive to board

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Eidos Therapeutics appoints former Portola executive to board

Eidos Therapeutics Inc. appointed William Lis to its board, effective Dec. 4.

Lis recently was CEO and a director of biopharmaceutical company Portola Pharmaceuticals Inc.

Additionally, Hoyoung Huh stepped down as a director of Eidos.

Eidos Therapeutics is a clinical-stage biopharmaceutical company that develops drugs to treat diseases caused by the neurodegenerative disease transthyretin amyloidosis.